List view / Grid view
Her leadership experience spans three decades with Lilly, across multiple…
Her leadership experience spans three decades with Lilly, across multiple therapeutic areas including oncology, neuroscience and infectious disease.
Subject to regulatory approval, the small molecule drug could provide…
Subject to regulatory approval, the small molecule drug could provide a new treatment option for diabetes and obesity, Eli Lilly’s new data suggests.
Dave Elder reflects on the array of applications for AI…
Dave Elder reflects on the array of applications for AI to facilitate successful drug development, though proof remains elusive.
As a promising treatment for type 2 diabetes and obesity,…
As a promising treatment for type 2 diabetes and obesity, based on key trial data, the market for glucagon-like peptide-1 receptor (GLP-1R) therapies looks set to generate major sales up to 2030.
The new Executive Vice President (EVP) has over “25 years…
The new Executive Vice President (EVP) has over “25 years of experience and a proven track record of leading strategic quality initiatives”, Eli Lilly and Company shared.
Eli Lilly and Company has committed the largest US investment…
Eli Lilly and Company has committed the largest US investment in synthetic medicine active pharmaceutical ingredient (API) manufacturing.
Following her leading contribution in key manufacturing and quality projects…
Following her leading contribution in key manufacturing and quality projects in Ireland and the US, Eli Lilly and Company’s Executive Vice President (EVP) of Global Quality is set to retire after nearly 35 years of service.
![Eli Lilly logo sign [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Eli-Lilly-300x278.jpg)
![Eli Lilly logo sign [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Eli-Lilly-e1629971959212.jpg)
Eli Lilly and Company announces plans to establish two new…
Eli Lilly and Company announces plans to establish two new manufacturing facilities in Indiana USA worth $2.1 billion.
Eli Lilly and Company have announced executive leadership changes and…
Eli Lilly and Company have announced executive leadership changes and the creation of neuroscience and immunology business units.
The human medicines committee decided that there was significant evidence…
The human medicines committee decided that there was significant evidence to endorse the use of a combination of bamlanivimab and etesevimab in outpatients at high risk of severe COVID-19.
Eli Lilly will provide the US government with vials of…
Eli Lilly will provide the US government with vials of its COVID-19 antibody therapy bamlanivimab (LY-CoV555) if the treatment is granted Emergency Use Authorisation.
Lilly, Merck and Pfizer have announced how they will enable…
Lilly, Merck and Pfizer have announced how they will enable their employees to volunteer in programmes to combat COVID-19 while on base pay.
The International Federation of Pharmaceutical Manufacturers and Associations has announced…
The International Federation of Pharmaceutical Manufacturers and Associations has announced that the biopharma industry has responding swiftly to the COVID-19 pandemic and will further increase its efforts.
Sanofi and Eli Lilly and Company announced an agreement to…
28 May 2014 | By Sanofi
Sanofi and Eli Lilly and Company announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil)...
Cognizant, announced that it has been selected by Eli Lilly…
20 January 2011 | By Brands2Life
Cognizant, announced that it has been selected by Eli Lilly and Company...
